Arena Obesity Drug Meets Goals, But Falls Short of Competitors ... Comtex Smartrend - New York,NY,USA Orexigen Therapeutics Inc.'s (NASDAQ:OREX) Contrave and Vivus Inc.'s (NASDAQ:VVUS) Qnexa proved to be more effective in late-stage trials reported this year ... | |
RTT News - Williamsville,NY,USA Biopharmaceutical company Orexigen Therapeutics, Inc. (OREX: News ) said in July that its obesity drug Contrave or bupropion SR/naltrexone SR met co-primary ... | |
Biotechs Race To Be The Biggest Loser Investor's Business Daily The three drugs, Orexigen's Contrave, Lorcaserin from Arena (ARNA) and Qnexa from Vivus (VVUS), have different ways of reducing food consumption. ... See all stories on this topic | |
Lorcaserin's Data Offset Modest Efficacy; Arena Plans NDA BioWorld Online Arena also is hoping that lorcaserin's composition also might give it a leg up in the partnering race, since both Vivus' Qnexa and Orexigen's Contrave are ... See all stories on this topic |
YOU CAN GET THE BODDY YOU WANT
TAGS:Weigh, waight , wieght. Weigth, weigt, rapid weight loss, loose weight,
weightloss